<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1487">
  <stage>Registered</stage>
  <submitdate>25/07/2006</submitdate>
  <approvaldate>12/01/2007</approvaldate>
  <actrnumber>ACTRN12607000042448</actrnumber>
  <trial_identification>
    <studytitle>Epoetin and cardiac function:An echocardiographic analysis in patients with heart failure.</studytitle>
    <scientifictitle>Improved cardiac function  following the acute intravenous administration of epoetin alpha in patients with heart failure. An echocardiographic, placebo controlled study.</scientifictitle>
    <utrn />
    <trialacronym>Nil</trialacronym>
    <secondaryid>Therapeutic Goods Administration (TGA): 2006/100</secondaryid>
    <secondaryid>Therapeutic Goods Administration (TGA): Protocol Number: V1 16MAY2005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiac failure.</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous administration of epoetin alpha(10,000U)and subsequent echocardiography(45 &amp; 120 min later)-then after a 135 min washout period,a small volume ( 1 ml)normal saline ( placebo) is given followed by repeat echocardiography 45 &amp; 120 min later.Trial drug and placebo given only once.</interventions>
    <comparator>After a 135 min washout period,a small volume ( 1 ml)normal saline ( placebo) is given followed by repeat echocardiography 45 &amp; 120 min later.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improved cardiac function including increased ejection fraction (echocardiography)</outcome>
      <timepoint>At 45 &amp; 120 mins.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any form of cadiac failure.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to epoetin alpha.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Nurse giving I/V injection not involved in study analysis.Use of sealed numbered envelopes.</concealment>
    <sequence>Coin tossing.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Subject ,echocardiographer , person performing pulse wave velocity are blinded.Only nurse who gives i/v placebo or epoetin is aware but has no role in study analysis.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Departments of Cardiovascular Medicine and Nephrology,John Hunter Hospital.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Hunter Area Health Service</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Janssen Cilag Pty Ltd.</fundingname>
      <fundingaddress />
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Janssen Cilag Pty Ltd.</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A preliminary study to evaluate the acute effect (2 hours) of a commonly used treatment for anaemia in renal failure on cardiac function (strength) in patients with cardiac failure.The potential benefits are based on a recent study(unpublished) that observed an effect of intravenous epoetin alpha on heart and large blood vessel (aorta) function.Patient and echocardiographer blinded to treatment/placebo order.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>John Hunter Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>04/12/08/3.19</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bruce Bastian</name>
      <address>Depertment of Cardiovascular Medicine
Locked Bag No 1
Newcastle Mail Centre NSW 2310</address>
      <phone>+61 2 49214207</phone>
      <fax>+61 2 49214210</fax>
      <email>Bruce.Bastian@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shane Lachlan Carney</name>
      <address>Department of Nephrology
John Hunter Hospital
Locked Bag No 1
Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 49214333</phone>
      <fax>+61 2 49214339</fax>
      <email>Shane.Carney@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>